Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Debt (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Total Debt for 11 consecutive years, with $370000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Total Debt changed N/A year-over-year to $370000.0, compared with a TTM value of $370000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $360000.0, changed N/A over the prior year.
  • Total Debt was $370000.0 for Q2 2025 at Avalo Therapeutics, up from $360000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $32.8 million in Q4 2021 and bottomed at $360000.0 in Q4 2024.
  • Average Total Debt over 5 years is $11.6 million, with a median of $12.0 million recorded in 2022.
  • Peak annual rise in Total Debt hit 58.93% in 2022, while the deepest fall reached 58.93% in 2022.
  • Year by year, Total Debt stood at $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023, then crashed by 96.56% to $360000.0 in 2024, then grew by 2.78% to $370000.0 in 2025.
  • Business Quant data shows Total Debt for AVTX at $370000.0 in Q2 2025, $360000.0 in Q1 2025, and $360000.0 in Q4 2024.